SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, SAGE, SOL on Behalf of Shareholders

23.06.25 19:30 Uhr

Werte in diesem Artikel

NEW YORK, June 23, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Halper Sadeh LLC (PRNewsfoto/Halper Sadeh LLP)

Blueprint Medicines Corporation (NASDAQ: BPMC)'s sale to Sanofi. Under the terms of the proposed transaction, Sanofi will pay $129.00 per share in cash at closing, and Blueprint shareholders also will receive one non-tradeable contingent value right (CVR) entitling the holder to receive two potential milestone payments of $2.00 and $4.00 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. If you are a Blueprint shareholder, click here to learn more about your legal rights and options.

Sage Therapeutics, Inc. (NASDAQ: SAGE)'s sale to Supernus Pharmaceuticals, Inc. Under the terms of the proposed transaction, Sage shareholders will receive $8.50 per share in cash, plus one non-tradable contingent value right collectively worth up to $3.50 per share in cash payable upon achieving certain net sales and commercial milestones. If you are a Sage shareholder, click here to learn more about your legal rights and options.

Emeren Group Ltd. (NYSE: SOL)'s sale to Shurya Vitra Ltd. for $0.20 in cash per ordinary share or $2.00 in cash per American Depositary Share. If you are an Emeren shareholder, click here to learn more about your legal rights and options.

Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-investigation-halper-sadeh-llc-investigates-bpmc-sage-sol-on-behalf-of-shareholders-302488394.html

SOURCE Halper Sadeh LLP

In eigener Sache

Übrigens: Blueprint Medicines und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Blueprint Medicines

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Blueprint Medicines

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Emeren Group Ltd (spons. ADRs)

Wer­bung

Analysen zu Emeren Group Ltd (spons. ADRs)

DatumRatingAnalyst
02.05.2019Renesola OutperformImperial Capital
16.12.2015Renesola BuyROTH Capital Partners, LLC
03.06.2015Renesola NeutralROTH Capital Partners, LLC
28.11.2014Renesola NeutralROTH Capital Partners, LLC
26.10.2011Renesola neutralPiper Jaffray & Co.
DatumRatingAnalyst
02.05.2019Renesola OutperformImperial Capital
16.12.2015Renesola BuyROTH Capital Partners, LLC
13.07.2011Renesola overweightPiper Jaffray & Co.
DatumRatingAnalyst
03.06.2015Renesola NeutralROTH Capital Partners, LLC
28.11.2014Renesola NeutralROTH Capital Partners, LLC
26.10.2011Renesola neutralPiper Jaffray & Co.
11.08.2011Renesola neutralROTH Capital Partners, LLC
10.08.2011Renesola neutralCredit Suisse Group
DatumRatingAnalyst
11.07.2011Renesola sellGoldman Sachs Group Inc.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Emeren Group Ltd (spons. ADRs) nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen